2024 Award Winners

Congratulations to the winners of the 2024 Canadian Healthcare Industry Awards!

Company of the Year 2023

Incyte logo

Emerging Company of the Year 2023

Roche logo

Community Leadership 2023

Product of the Year 2023

Brigitte Nolet

LifeSci Executive of the Year 2023

Brad Donoff

Sales Professional of the Year 2023

Learn More:

GSK Canada

(GlaxoSmithKline Inc.)

In 2023, GSK launched a vaccine that has the potential to save thousands of lives a year in North America, expanded options for the treatment of endometrial cancer, and demonstrated industry leadership in environmental action, healthy workplaces, and corporate giving.

In August, Health Canada authorized Arexvy®, the first and only respiratory syncytial virus (RSV) vaccine available in Canada for older adults. After Phase II trials showed Arexvy was 82.6% efficacious in preventing lower respiratory tract disease caused by RSV in adults over 60, Time Magazine named the vaccine a Best Invention of 2023. RSV is estimated to hospitalize tens of thousands of older adults each year in Canada, and the vaccine is expected to dramatically lower RSV-related morbidity and mortality.

In another important development, Health Canada approved an expanded indication for GSK’s Jemperli® in the treatment of endometrial cancer. About 8,100 new cases of endometrial cancer are diagnosed every year in Canada. Jemperli, approved in combination with chemotherapy, is the only immunotherapy treatment approved for this patient population.

With its focus on four key areas – infectious diseases, HIV, oncology, and immunology – GSK has consistently ranked among Canada’s Top 100 Corporate R&D Spenders through its health research.

Recognizing that the most important investment is its people, GSK has built an inclusive workplace culture that encourages opportunities for growth as well as connection. The company provides mandatory company-wide mandatory training in mental health promotion and facilitates hybrid work schedules as well as employee resource groups.

GSK was also recognized for its charitable investments, vaccine access advocacy, and environmental initiatives. In 2023, GSK supported the Canadian Institutes of Health Research Lung Health Team with a $2 million grant, representing the largest private financial contribution to the initiative to date. In November, GSK partnered with front-line healthcare workers, academics, public health experts, patient groups and other industry leaders to launch Canada’s Adult Vaccine Alliance (AVA), which aims to increase access to National Advisory Committee on Immunization (NACI)-recommended adult vaccines in Canada. GSK has continued to eliminate single-use plastics from its manufacturing processes, as well as reduce water consumption and improve landfill diversion.

For bringing life-saving innovations to Canadian patients, demonstrating remarkable environmental and social responsibility and championing employee wellness, GSK is the CHIA Company of the Year 2023.

Incyte logo

Incyte Biosciences Canada

Incyte Biosciences Canada has maintained an unwavering focus on unmet medical needs in rare diseases and achieved impressive commercialization achievements in just under three years of operation. Within one year of opening its Montreal headquarters, the company secured Health Canada’s conditional market authorization for two first-in-class oncology drugs, Minjuvi® (tafasitamab) and Pemazyre® (pemigatinib).

In 2023, Minjuvi was approved in Québec for public reimbursement for patients living with relapsed or refractory diffuse large B-cell lymphoma. The same year, in a long-awaited move, Québec’s Institut National d’Excellence en Santé et en Services Sociaux (INESSS) positively recommended Pemazyre, the first targeted drug in Canada for fibroblast growth factor receptor 2 (FGFR2)‑positive intrahepatic cholangiocarcinoma (iCCA). Incyte Biosciences Canada has also filed for Health Canada’s authorization of Opzelura® in the treatment of atopic dermatitis and vitiligo.

Alongside these important milestones, Incyte Biosciences Canada has expanded its reach, with nearly 50 employees across the country; invested over $40 million in Canadian academic and scientific collaborations; and launched 35 clinical trials.

Collaborating with patient stakeholders, rare disease advocacy groups, and policy organizations, Incyte Biosciences Canada has worked to break down barriers to drug access for Canadians who need innovative medicines.

Exemplifying its commitment to Canadian patients with rare diseases, Incyte partnered with OncoHelix, a Calgary-based genomic testing company, to remove barriers and fully fund FGFR2 testing for all Canadians diagnosed with iCCA. An estimated 10% to 20% of people with iCCA have FGFR2 fusions or rearrangements. Thanks in part to the success of this collaboration, in November 2023, Ontario began publicly funding optimal genomic testing for iCCA patients.

To address knowledge gaps and promote optimal testing and precision therapy, Incyte launched Target CCA, a multidisciplinary learning program designed in partnership with leading Canadian pathologists, surgeons, and medical oncologists. Since 2021, Target CCA has reached 1,500 healthcare providers across the country.With its determined commitment to rare disease patients in a challenging pricing and reimbursement environment, Incyte is a welcome and exciting addition to the Canadian healthcare industry and a deserving honouree as CHIA Emerging Company of the Year 2023.

Roche logo

Hoffmann-La Roche Limited

(Roche Canada)

Roche Canada is honoured for its commitment to local and global communities. The Mississauga-based pharmaceutical company gives back through volunteerism, philanthropy, day-to-day corporate practices, and employee sustainability incentives.

Every year, Roche Canada provides all employees with one paid day to devote to volunteering. In 2023, Roche Canada employees dedicated over 500 volunteer hours to causes that were important to them. Employees helped to build homes for families with Habitat for Humanity GTA, removed an invasive species from the Riverwood Conservancy, spring cleaned at the Darling Home for Kids, and assembled essential items for people living with homelessness through the Shoebox Project, among other contributions.

Roche Canada also stood out in its philanthropy. The company donated close to $250,000 to a variety of Canadian charities in 2023. Partnering with MicroHabitat, Roche Canada also built a rooftop urban garden at its Mississauga headquarters that produced 500 pounds of vegetables and herbs in 2023 for local food banks. Alongside Roche employees around the world, in June of 2023, 500 Roche Canada employees participated in the Roche Children’s Walk. Along with a corporate match, Roche Canada employees raised over $41,000 in funds for local and global children’s projects.

Roche Canada also demonstrated excellence in its environmental stewardship initiatives. A Leadership in Energy and Environmental Design (LEED)-certified office, Roche Canada met ambitious energy conservation goals, reduced business flights and switched to ozone-friendly mechanical equipment while making progress on fleet fuel efficiency. Roche Canada also invested in employee awareness activities and supply chain improvements to ensure that 95% of all waste generated goes to recycling programs. In 2023, Roche Canada installed free electric vehicle (EV) chargers at their Mississauga head office. The company offers carpooling incentives and on-site covered bike racks. It is also piloting a shuttle service from a nearby subway station to encourage employees to take transit to work.

Roche Canada’s community initiatives demonstrate the mutually beneficial impact of giving back while fostering engagement and excitement among team members. The CHIA award for Community Leadership recognizes the myriad, inspired ways that Roche Canada lives its mission of creating a better tomorrow.

Brigitte Nolet

Brigitte Nolet

(Hoffmann-LaRoche Limited)

As President and CEO of Hoffmann-LaRoche Limited (Roche Canada), Brigitte Nolet leads a diverse team of nearly 2,000 employees working together to bring novel healthcare solutions to Canadians.

Recognizing that Canadian patients face wait times for coverage of newly approved medicines that are nearly twice as long as most peer countries, Brigitte has joined forces with key health stakeholders to remove barriers to access. She has advocated for meaningful changes in Canada’s drug approval and reimbursement processes in national media interviews and as a speaker at major healthcare conferences.

Last fall, Brigitte was appointed Chair of the Board of Directors for Innovative Medicines Canada, where she works alongside industry partners to champion policies that drive the discovery, development, and delivery of transformative medicines and vaccines to all Canadians.

Brigitte has also been advocating for the implementation of a strong and integrated national health data infrastructure, to support faster, more data-driven decisions in healthcare that would ensure innovative treatments reach the patients who most need them.

Internally, Brigitte has made it a priority to revitalize company culture and employee engagement in a post‑pandemic work landscape. In the last year, she has led a series of team-building initiatives and created more transparent communication channels to understand employees’ needs and support teams’ successful integration back into physical offices.

A member of the Healthcare Businesswomen’s Association’s partner advisory board, Brigitte also promotes innovation in women’s healthcare and champions the involvement of more women at all levels, from clinical trial research to health industry boardrooms.

The CHIA award for LifeSci Executive of the Year 2023 recognizes Brigitte’s determination not only to deliver breakthrough medical innovations, but to also collaborate with stakeholders across the health ecosystem to ensure those innovations can have the biggest impact possible.

Brad Donoff

Brad Donoff

(Valeo Pharma)

As a regional sales director, Brad Donoff has been instrumental in the expansion of Valeo Pharma’s respiratory division, consisting of the Enerzair® and Atectura® Breezhaler® products. Brad provides team members with an overall strategic framework and desired outcomes, and then empowers each team member to meet their targets by utilizing their unique skills and expertise. His approach offers sales representatives the freedom to engage health professionals based on local needs in formats most preferred by those professionals, whether that be one‑on‑one meetings, educational programs, or other approaches.

Brad leads by example, frequently working full days alongside his team members in the field to show his commitment and offer individualized coaching and mentoring.

He believes in recognizing both the big and small achievements of his team members on their paths to success. This consistent encouragement inspires his team to not only meet, but exceed, their sales goals. With their hard work and commitment to excellence, Brad’s team has consistently ranked as the #1 performing team across Canada.

After the Enerzair and Atectura Breezhaler products launched in mid‑2021, Brad and his team were tasked with introducing the new, once-daily asthma inhalers to physicians. Well-aware of the importance of education and prescriber support, Brad ensured that his team members fully understood the evidence behind the products, including the products’ mechanisms of action, safety profile, and more, so that they could offer comprehensive answers to providers’ questions. Above all, Brad has created a culture where team members are intrinsically motivated to grow providers’ awareness of new therapeutic options that improve patients’ day‑to‑day lives.

Brad’s exceptional leadership and his team’s successes haves rightfully earned him recognition as the inaugural CHIA Sales Professional of the Year 2023.